Clinical Trials Directory

Trials / Completed

CompletedNCT00251732

Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)

Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI.

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
150 (actual)
Sponsor
University of Arizona · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The main objective of this study is to evaluate the role of pain modulation in GERD patients who fail to obtain clinical relief with standard dose (once daily) PPI. The study will compare the efficacy of 1) standard dose PPI plus low-dose tricyclic antidepressant (TCA) to, 2) double dose PPI to, 3) standard dose PPI and placebo to determine the relative symptom resolution and health related quality of life in GERD patients who fail standard dose PPI and are randomly assigned to one of these three groups.

Detailed description

To evaluate the role of pain modulation in gastroesophageal reflux disease(GERD)patients who fail to obtain clinical relief with standard dose (once daily) proton pump inhibitor(PPI). The study will compare the efficacy; of 1)standard dose PPI plus low-dose tricyclic antidepressant (TCA) to, 2) double dose PPI to, 3) standard dose PPI and placebo to determine the relative symptom resolution and health related quality of life in GERD patients who fail standard dose PPI and are randomly assigned to one of these three groups.

Conditions

Interventions

TypeNameDescription
DRUGStandard dose (once daily) PPI plus low-dose antidepressant20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)
DRUGDouble dose PPI plus evening placebo20 mg. twice daily with a placebo
DRUGRabeprazole , placebo, placebo20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime

Timeline

Start date
2005-03-01
Primary completion
2010-05-01
Completion
2010-05-01
First posted
2005-11-10
Last updated
2010-08-19

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00251732. Inclusion in this directory is not an endorsement.